Pfizer Inc. (0Q1N.IL)

27,75 +0,10 (+0,36 %) À partir de 08:39AM BST. Marché ouvert.

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 83 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Albert Bourla D.V.M., Ph.D.	Chairman & CEO	11,72M	S.O.	1962
Mr. Frank A. D'Amelio	CFO & Exec. VP	S.O.	S.O.	1958
Mr. David M. Denton	Chief Financial Officer & Exec. VP	18,19M	S.O.	1965
Dr. Mikael Dolsten M.D., Ph.D.	Chief Scientific Officer and Pres of R&D	5,82M	S.O.	1958
Ms. Angela Hwang	Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus.	4,89M	7,7M	1966
Ms. Jennifer B. Damico	Sr. VP, Controller & Principal Accounting Officer	S.O.	S.O.	1968
Ms. Lidia L. Fonseca	Exec. VP and Chief Digital & Technology Officer	S.O.	S.O.	1969
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	S.O.	S.O.	S.O.
Mr. Douglas M. Lankler	Exec. VP & Gen. Counsel	S.O.	S.O.	1966
Mr. Rady A. Johnson	Exec. VP and Chief Compliance, Quality & Risk Officer	S.O.	S.O.	1962

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Pfizer Inc. en date du 1 octobre 2023 est 5. Les scores principaux sont Audit : 10; Société : 5; Droits des actionnaires : 1; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.